3 results
The project*s overarching aim is to diminish respiratory disease burden in moderate-late preterm born infants in their first 18 months of life. We have formulated the following specific objectives: 1. Determine whether the introduction of our follow…
Primary:To evaluate the efficacy and safety of Ensartinib vs. crizotinib in patients with ALK-positive NSCLC that have received up to 1 prior chemotherapy regimen and no prior ALK tyrosine kinase inhibitor (TKI).Secondary:To obtain additional…
Primary:To evaluate the effects of pirepemat on falls frequency as compared to placebo.Secundary:To evaluate the effects of pirepemat on Parkinson's disease motor symptoms as compared to placebo.To evaluate the effects of pirepemat on apathy as…